Holding ANDA Labeling Review Until Late Cycle Could Minimize Delays From Last-Minute Changes

 
• By Derrick Gingery

A GDUFA III adjustment could allow more labeling changes during the review cycle and reduce assessment cycles.

Clock near deadline
FDA agreed to issue the ANDA labeling assessment closer to the goal date in order to avoid delays from late changes by reference product sponsors. • Source: Alamy

More from Generics

More from Biosimilars & Generics